Apollomics Regains Compliance with Nasdaq’s Minimum Bid Price Requirement
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 10 2024
0mins
Should l Buy ?
Source: Globenewswire
Regaining Compliance: Apollomics Inc. has regained compliance with Nasdaq's minimum bid price requirement, as confirmed by a notification from Nasdaq on December 10, 2024, stating that the company's Class A ordinary shares closed at $1.00 or greater for ten consecutive business days.
Company Overview: Apollomics is a clinical-stage biopharmaceutical company focused on developing oncology therapies, including its lead program vebreltinib (APL-101), a selective c-Met inhibitor currently in Phase 2 trials for non-small cell lung cancer and other advanced tumors.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
